Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy.

Alkazemi MH, Brousell S, Fantony J, Tsivian M, Moul JW.

Urology. 2018 Aug 23. pii: S0090-4295(18)30688-5. doi: 10.1016/j.urology.2018.06.043. [Epub ahead of print] No abstract available.

PMID:
30009841
2.

Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis.

Kowalewski KF, Tapking C, Hetjens S, Nickel F, Mandel P, Nuhn P, Ritter M, Moul JW, Thüroff JW, Kriegmair MC.

Eur Urol Focus. 2018 Jun 12. pii: S2405-4569(18)30143-3. doi: 10.1016/j.euf.2018.05.009. [Epub ahead of print] Review.

PMID:
29907547
3.

Yes or no to local therapy for oligometastatic prostate cancer?

Moul JW.

Nat Rev Urol. 2018 Jul;15(7):399-400. doi: 10.1038/s41585-018-0028-7. No abstract available.

PMID:
29795250
4.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
5.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED.

Ther Adv Urol. 2017 Nov 22;10(2):43-50. doi: 10.1177/1756287217738150. eCollection 2018 Feb.

6.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

8.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G.

Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. doi: 10.1016/j.clgc.2017.10.001. Epub 2017 Oct 16.

PMID:
29173976
9.

Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?

Gansler T, Fedewa S, Qi R, Lin CC, Jemal A, Moul JW.

J Urol. 2018 Mar;199(3):706-712. doi: 10.1016/j.juro.2017.10.014. Epub 2017 Oct 12.

PMID:
29032296
10.

Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.

Qi R, Foo WC, Ferrandino MN, Davis LG, Sekar S, Longo TA, Jibara G, Han T, Gokhan I, Moul JW.

Can J Urol. 2017 Oct;24(5):8982-8989.

PMID:
28971784
11.

Editorial Comment.

Moul JW.

J Urol. 2017 Dec;198(6):1300. doi: 10.1016/j.juro.2017.07.090. Epub 2017 Sep 1. No abstract available.

PMID:
28867072
12.

The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ.

Curr Urol Rep. 2017 Jul;18(7):52. doi: 10.1007/s11934-017-0699-2. Review.

PMID:
28589398
13.

Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?

Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, Moul JW, Polascik TJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):323-327. doi: 10.1038/pcan.2017.20. Epub 2017 Apr 25.

PMID:
28440322
14.

How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?

Madden-Fuentes RJ, Koontz BF, Harrison MR, George DJ, Davidson B, Gilmore BF, Moul JW, Mantyh C, Peterson AC.

Oncology (Williston Park). 2017 Apr 15;31(4):286-94. Review.

15.

Comparison of DRE and PSA in the Detection of Prostate Cancer.

Moul JW.

J Urol. 2017 Feb;197(2S):S208-S209. doi: 10.1016/j.juro.2016.11.031. Epub 2016 Dec 20. No abstract available.

PMID:
28010975
16.

Editorial Comment.

Moul JW.

Urology. 2017 Jan;99:74. doi: 10.1016/j.urology.2016.09.047. Epub 2016 Nov 11. No abstract available.

PMID:
27839903
17.

Rising PSA Level in an Anxious Postprostatectomy Patient.

Qi R, Moul JW.

Oncology (Williston Park). 2016 Sep 15;30(9):834-7, 860. No abstract available.

18.

Role of salvage lymph node dissection in prostate cancer.

Heidenreich A, Moul JW, Shariat S, Karnes RJ.

Curr Opin Urol. 2016 Nov;26(6):581-9. doi: 10.1097/MOU.0000000000000343. Review.

PMID:
27584024
19.

Editorial Comment.

Moul JW.

J Urol. 2016 Sep;196(3):732. doi: 10.1016/j.juro.2016.03.185. Epub 2016 Jun 2. No abstract available.

PMID:
27264352
20.

Editorial comment.

Moul JW.

Urology. 2016 Jan;87:131-2. No abstract available.

PMID:
27243084
21.

Editorial Comment.

Moul JW, Semans JH.

Urology. 2016 Jul;93:66-7. doi: 10.1016/j.urology.2015.11.067. Epub 2016 Apr 22. No abstract available.

PMID:
27113492
22.

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P, Wood S, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, Anand M, Bratt L, Kim S, Tran PT, George DJ; Department of Defense Prostate Cancer Clinical Trials Consortium.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):100-6. doi: 10.1038/pcan.2015.59. Epub 2016 Jan 12.

PMID:
26754260
23.

Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.

Sutton SS, Crawford ED, Moul JW, Hardin JW, Kruep E.

World J Urol. 2016 Aug;34(8):1107-13. doi: 10.1007/s00345-015-1754-6. Epub 2016 Jan 11.

PMID:
26753559
24.

Prostate cancer in men of African origin.

McGinley KF, Tay KJ, Moul JW.

Nat Rev Urol. 2016 Feb;13(2):99-107. doi: 10.1038/nrurol.2015.298. Epub 2015 Dec 31. Review.

PMID:
26718455
25.

Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls.

Tay KJ, Gupta RT, Rastinehad AR, Tsivian E, Freedland SJ, Moul JW, Polascik TJ.

Expert Rev Anticancer Ther. 2016;16(3):303-11. doi: 10.1586/14737140.2016.1131155. Epub 2016 Feb 18. Review.

PMID:
26653079
26.

Screening for familial and hereditary prostate cancer.

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5. Review.

27.

Management of Prostate Cancer in the Elderly.

Tay KJ, Moul JW, Armstrong AJ.

Clin Geriatr Med. 2016 Feb;32(1):113-32. doi: 10.1016/j.cger.2015.08.001. Epub 2015 Oct 14. Review.

PMID:
26614864
28.

Editorial Comment.

Moul JW.

Urology. 2015 Oct;86(4):788. doi: 10.1016/j.urology.2015.05.035. Epub 2015 Aug 29. No abstract available.

PMID:
26324000
29.

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.

Crawford ED, Moul JW, Sartor O, Shore ND.

Expert Opin Drug Metab Toxicol. 2015;11(9):1465-74. doi: 10.1517/17425255.2015.1073711. Review.

PMID:
26293510
30.

Hot topic of cancer survivorship and the 'seven deadly sins'.

Moul JW.

BJU Int. 2015 Sep;116(3):310-1. doi: 10.1111/bju.13115. No abstract available.

31.

Hormone naïve prostate cancer: predicting and maximizing response intervals.

Moul JW.

Asian J Androl. 2015 Nov-Dec;17(6):929-35; discussion 933. doi: 10.4103/1008-682X.152821. Review.

32.

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Davis K, Wood S, Dill E, Fesko Y, Bitting RL, Harrison MR, Armstrong AJ, Moul JW, George DJ.

Clin J Oncol Nurs. 2015 Jun;19(3):297-303. doi: 10.1188/15.CJON.297-303.

PMID:
26000580
33.

High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care.

Moul JW.

Urol Oncol. 2015 May;33(5):206-7. doi: 10.1016/j.urolonc.2015.03.004. Epub 2015 Apr 4. No abstract available.

PMID:
25851744
34.

Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer.

Polascik TJ, Tay KJ, Moul JW.

Eur Urol. 2015 Dec;68(6):937-8. doi: 10.1016/j.eururo.2015.02.024. Epub 2015 Mar 11. No abstract available.

PMID:
25770483
35.

Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?

Tay KJ, Mendez M, Moul JW, Polascik TJ.

Curr Opin Urol. 2015 May;25(3):185-90. doi: 10.1097/MOU.0000000000000168. Review.

PMID:
25768694
36.

ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.

Crawford ED, Moul JW.

Oncology (Williston Park). 2015 Jan;29(1):55-8, 65-6. Review.

37.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW.

Rev Urol. 2014;16(4):172-80.

38.

Editorial comment.

Moul JW, Semans JH.

Urology. 2015 Jan;85(1):90. doi: 10.1016/j.urology.2014.07.073. Epub 2014 Nov 11. No abstract available.

PMID:
25530369
39.

Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial.

Azrad M, Vollmer RT, Madden J, Polascik TJ, Snyder DC, Ruffin MT 4th, Moul JW, Brenner D, He X, Demark-Wahnefried W.

Biotech Histochem. 2015 Apr;90(3):184-9. doi: 10.3109/10520295.2014.976840. Epub 2014 Dec 1.

40.

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA.

Urology. 2014 Dec;84(6):1427-32. doi: 10.1016/j.urology.2014.07.059.

PMID:
25432832
41.

The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.

Moul JW.

Oncology (Williston Park). 2014 Aug;28(8):702-3, 722. No abstract available.

42.
43.

Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?

Stewart SB, Moul JW, Polascik TJ, Koontz BF, Robertson CN, Freedland SJ, George DJ, Lee WR, Armstrong AJ, Bañez LL.

Int J Urol. 2014 Dec;21(12):1215-9. doi: 10.1111/iju.12561. Epub 2014 Jul 14.

44.

Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy.

Moul JW, Chen DY, Trabulsi EJ, Warlick CA, Ruckle HC, Porter JR, Yoshida JS, Adams GW, Kella N, Matsunaga GS, Bans LL, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA; investigators of the ProsVue Field Experience Trial.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):280-5. doi: 10.1038/pcan.2014.25. Epub 2014 Jul 15.

PMID:
25027863
45.

Utility of LHRH antagonists for advanced prostate cancer.

Moul JW.

Can J Urol. 2014 Apr;21(2 Supp 1):22-7. Review.

46.

Active surveillance for African-American men with prostate cancer: of course! Pro.

Moul JW.

Oncology (Williston Park). 2014 Jan;28(1):82, 84-5. No abstract available.

47.

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Crawford ED, Shore ND, Moul JW, Tombal B, Schröder FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Klotz L.

Urology. 2014 May;83(5):1122-8. doi: 10.1016/j.urology.2014.01.013. Epub 2014 Mar 22.

PMID:
24661333
48.

Awareness, concern, and communication between physicians and patients on bone health in cancer.

Tripathy D, Durie BG, Mautner B, Ferenz KS, Moul JW.

Support Care Cancer. 2014 Jun;22(6):1601-10. doi: 10.1007/s00520-014-2127-1. Epub 2014 Jan 30.

PMID:
24477326
49.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ.

J Clin Oncol. 2014 Mar 1;32(7):671-7. doi: 10.1200/JCO.2013.52.3696. Epub 2014 Jan 21. Erratum in: J Clin Oncol. 2014 May 1;32(13):1387.

50.

Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial.

Habib AS, Moul JW, Polascik TJ, Robertson CN, Roche AM, White WD, Hill SE, Nosnick I, Gan TJ; Duke Perioperative Outcome Study Group.

Curr Med Res Opin. 2014 May;30(5):937-43. doi: 10.1185/03007995.2013.877436. Epub 2014 Jan 24.

PMID:
24351100

Supplemental Content

Support Center